REGULATION OF CORONARY ARTERY MYOGENIC TONE BY PKG
PKG 对冠状动脉肌原张力的调节
基本信息
- 批准号:6530609
- 负责人:
- 金额:$ 4.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-03-01 至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Maintenance of adequate coronary artery blood flow is essential for life. Nitric oxide (NO) may play a critical role in the regulation of flow by opposing vascular smooth muscle (VSM) contraction and restricting the development of coronary artery tone. In fact, enhanced tonic release of NO from coronary endothelium is believed to account, at least in part, for the cardioprotective effect of circulating estrogen in premenopausal women. It is widely believed that the vasodillatory influence of NO is mediated predominantly through the action of cGMP dependent protein kinase (PKG) in smooth muscle cells. However, due primarily to the lack of adequately selective inhibitors, the contribution of PKG to the regulation of vascular tone remains unclear.. New peptide inhibitors of PKG, recently developed in the laboratory of Dr. Wolgang Dostmann at the University of Vermont, may provide the selective tools needed to discern PKG dependence. These peptides are composed of potent, substrate-competitive PKG inhibitor sequences linked to carrier sequences (often referred to as "Trojan horse" peptides) that facilitate cellular uptake. Recent preliminary studies have revealed that the novel PKG inhibitor peptide, DT-3, effectively permeates cultured vascular smooth muscle cells and selectively inhibits PKG activity. In this project, specific PKG inhibitors including DT-3 will be employed to assess the role of PKG action will subsequently be addressed, primarily focusing on PKG dependent activation of Ca2+ sensitive potassium channels (K/Ca). The findings of this study will provide valuable insights into the fundamental mechanisms that determine cardiac blood flow.
维持足够的冠状动脉血流对生命至关重要。一氧化氮(NO)可能通过对抗血管平滑肌(VSM)收缩和限制冠状动脉张力的发展而在流量调节中起关键作用。事实上,从冠状动脉内皮增强的NO的紧张性释放被认为是绝经前妇女循环雌激素的心脏保护作用的原因,至少部分是如此。广泛认为NO的血管舒张作用主要通过平滑肌细胞中cGMP依赖性蛋白激酶(PKG)的作用介导。然而,主要由于缺乏足够的选择性抑制剂,PKG对血管张力调节的贡献仍不清楚。最近在佛蒙特大学的Wolfang Dostmann博士的实验室开发的PKG新肽抑制剂可能提供辨别PKG依赖性所需的选择性工具。这些肽由与促进细胞摄取的载体序列(通常称为“特洛伊木马”肽)连接的有效底物竞争性PKG抑制剂序列组成。最近的初步研究表明,新的PKG抑制剂肽DT-3,有效地渗透培养的血管平滑肌细胞和选择性抑制PKG活性。在本项目中,将采用包括DT-3在内的特异性PKG抑制剂来评估PKG作用的作用,随后将讨论PKG作用,主要关注PKG依赖性激活Ca 2+敏感性钾通道(K/Ca)。这项研究的结果将为确定心脏血流的基本机制提供有价值的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK STEPHEN TAYLOR其他文献
MARK STEPHEN TAYLOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK STEPHEN TAYLOR', 18)}}的其他基金
Network signature of low-flow endothelial dysfunction
低流量内皮功能障碍的网络特征
- 批准号:
10666476 - 财政年份:2021
- 资助金额:
$ 4.42万 - 项目类别:
Network signature of low-flow endothelial dysfunction
低流量内皮功能障碍的网络特征
- 批准号:
10475161 - 财政年份:2021
- 资助金额:
$ 4.42万 - 项目类别:
Network signature of low-flow endothelial dysfunction
低流量内皮功能障碍的网络特征
- 批准号:
10297926 - 财政年份:2021
- 资助金额:
$ 4.42万 - 项目类别:
Coronary Artery Regulation by Small Conduction Ca2+-activated K+ Channels
小传导 Ca2 激活 K 通道对冠状动脉的调节
- 批准号:
7501504 - 财政年份:2007
- 资助金额:
$ 4.42万 - 项目类别:
Coronary Artery Regulation by Small Conduction Ca2+-activated K+ Channels
小传导 Ca2 激活 K 通道对冠状动脉的调节
- 批准号:
7899940 - 财政年份:2007
- 资助金额:
$ 4.42万 - 项目类别:
Coronary Artery Regulation by Small Conduction Ca2+-activated K+ Channels
小传导 Ca2 激活 K 通道对冠状动脉的调节
- 批准号:
7315770 - 财政年份:2007
- 资助金额:
$ 4.42万 - 项目类别:
Coronary Artery Regulation by Small Conduction Ca2+-activated K+ Channels
小传导 Ca2 激活 K 通道对冠状动脉的调节
- 批准号:
7669270 - 财政年份:2007
- 资助金额:
$ 4.42万 - 项目类别:
REGULATION OF CORONARY ARTERY MYOGENIC TONE BY PKG
PKG 对冠状动脉肌原张力的调节
- 批准号:
6298954 - 财政年份:2001
- 资助金额:
$ 4.42万 - 项目类别:
相似海外基金
Living with Spontaneous Coronary Artery Dissection: A multicentre, patient-informed investigation
自发性冠状动脉夹层的生活:一项多中心、患者知情的调查
- 批准号:
481005 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
Development of nextgeneration cellular artificial blood vessels for coronary artery bypass surgery using bio-3D printer
使用生物 3D 打印机开发用于冠状动脉搭桥手术的下一代细胞人造血管
- 批准号:
23H02991 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Whole genome sequence interpretation for lipids to discover new genes and mechanisms for coronary artery disease
脂质的全基因组序列解释,以发现冠状动脉疾病的新基因和机制
- 批准号:
10722515 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
Molecular predictors of cardiovascular events and resilience in chronic coronary artery disease
心血管事件的分子预测因素和慢性冠状动脉疾病的恢复力
- 批准号:
10736587 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - UNIVERSITY OF MINNESOTA FIELD CENTER.
年轻人冠状动脉风险发展 (CARDIA) 研究 - 明尼苏达大学实地中心。
- 批准号:
10901060 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - COORDINATING CENTER (CC)
年轻人冠状动脉风险发展 (CARDIA) 研究 - 协调中心 (CC)
- 批准号:
10901063 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
Repetitive Stretch-Induced Myocardial Stiffening in Chronic Coronary Artery Disease
慢性冠状动脉疾病中反复牵拉引起的心肌硬化
- 批准号:
10588929 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
Sex-differences in 5 year survival with percutaneous coronary intervention compared to coronary artery bypass graft surgery in patients with diabetes and multivessel disease
糖尿病和多支血管疾病患者经皮冠状动脉介入治疗与冠状动脉搭桥手术的 5 年生存率存在性别差异
- 批准号:
495441 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics
DCAD - 利用新型 AI 增强型超快速蛋白质组学开发更好的冠状动脉疾病诊断方法
- 批准号:
10072712 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别:
Collaborative R&D
ADAR mediated RNA editing is a causal mechanism in coronary artery disease
ADAR 介导的 RNA 编辑是冠状动脉疾病的因果机制
- 批准号:
10629687 - 财政年份:2023
- 资助金额:
$ 4.42万 - 项目类别: